Invitrogen's Life Technolgies Buy Builds Life Science/Genomics Offerings
This article was originally published in The Gray Sheet
Executive Summary
The acquisition of Life Technologies, under a definitive $1.9 bil. agreement announced July 9, will enhance Invitrogen's life sciences and genomics product offerings, create a combined firm with revenues of over $500 mil. and about $100 mil. in operating cash flow, and generate anticipated cash earnings per share growth "in the range of 20-25%," Invitrogen says.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.